[1] Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer[J]. Trends Genet, 2021, 37(11): 1012-1027. DOI:10.1016/j.tig.2021.05.002.
[2] Patani H, Rushton MD, Higham J, et al. Transition to naïve human pluripotency mirrors pan-cancer DNA hypermethylation[J].Nat Commun,2020,11:3671. DOI:10.1038/s41467-020-17269-3.
[3] He J, He H, Qi Y, et al . Application of epigenetics in dermatological research and skin management[J].J Cosmet Dermatol,2022,21(5):1920-1930. DOI:10.1111/jocd.14355.
[4] Chen Z, Zhang Y . Role of Mammalian DNA Methyltransferases in Development[J]. Annu Rev Biochem, 2020, 89: 135-158. DOI:10.1146/annurev-biochem-103019-102815.
[5] Herman JG, Baylin SB . Gene silencing in cancer in association with promoter hypermethylation[J]. N Engl J Med, 2003, 349(21): 2042-2054. DOI:10.1056/NEJMra023075.
[6] Ressler JM, Tomasich E, Hatziioannou T, et al . DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma[J]. Target Oncol, 2024, 19(2): 263-275. DOI:10.1007/s11523-024-01041-4.
[7] Gao L, van den Hurk K, Moerkerk PTM, et al . Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy[J]. J Invest Dermatol, 2014, 134(12): 2957-2966. DOI:10.1038/jid.2014.270.
[8] Busch C, Geisler J, Lillehaug JR, et al . MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC[J]. Eur J Cancer, 2010, 46(11): 2127-2133. DOI:10.1016/j.ejca.2010.04.023.
[9] Mori T, O’Day SJ, Umetani N, et al . Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy[J]. J Clin Oncol, 2005, 23(36): 9351-9358. DOI:10.1200/JCO.2005.02.9876.
[10]Spugnardi M, Tommasi S, Dammann R, et al. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma[J]. Cancer Res, 2003, 63(7): 1639-1643. PMID:12670917.
[11]Pabalan N, Kunjantarachot A, Ruangpratheep C, et al . Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis[J]. Gynecol Oncol, 2017, 146(3): 603-608. DOI:10.1016/j.ygyno.2017.06.017.
[12]Meevassana J, Varophas S, Prabsattru P, et al . 5-Methylcytosine immunohistochemistry for predicting cutaneous melanoma prognosis[J]. Sci Rep, 2024, 14(1): 7554. DOI:10.1038/s41598-024-58011-z.
[13]Tellez CS, Shen L, Estécio MRH, et al . CpG island methylation profiling in human melanoma cell lines[J].Melanoma Res,2009,19(3):146-155. DOI:10.1097/cmr.0b013e32832b274e.
[14]Gillespie AM, Coleman RE . The potential of melanoma antigen expression in cancer therapy[J]. Cancer Treat Rev, 1999, 25(4): 219-227. DOI:10.1053/ctrv.1999.0126.
[15]Kuriyama Y, Shimizu A, Kanai S, et al . Expression of long interspersed nuclear elements-1 as a surrogate marker for global genomic hypomethylation of malignant skin tumors[J]. J Dermatol Sci, 2020, 99(3): 213-215. DOI:10.1016/j.jdermsci.2020.07.008.
[16]Tonella L, Pala V, Ponti R, et al . Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications[J]. Int J Mol Sci, 2021, 22(9). DOI:10.3390/ijms22094561.
[17]Cheng PF, Shakhova O, Widmer DS, et al . Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma[J]. Genome Biol, 2015, 16(1): 42. DOI:10.1186/s13059-015-0594-4.
[18]Seidl-Philipp M, Frischhut N, Höllweger N, et al . Known and new facts on basal cell carcinoma[J]. J Dtsch Dermatol Ges, 2021, 19(7): 1021-1041. DOI:10.1111/ddg.14580.
[19]Brinkhuizen T, van den Hurk K, Winnepenninckx VJL, et al . Epigenetic changes in Basal Cell Carcinoma affect SHH and WNT signaling components[J]. PloS One, 2012, 7(12): e51710. DOI:10.1371/journal.pone.0051710.
[20]Chiang A, Tan CZ, Kuonen F, et al . Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma[J]. J Invest Dermatol, 2019,139(11):2263-2271.e5. DOI:10.1016/j.jid.2019.03. 1163.
[21]Athar M, Li C, Kim AL, et al . Sonic hedgehog signaling in Basal cell nevus syndrome[J]. Cancer Res, 2014, 74(18): 4967-4975. DOI:10.1158/0008-5472.CAN-14-1666.
[22]Epstein EH . Basal cell carcinomas: attack of the hedgehog[J]. Nat Rev Cancer, 2008, 8(10): 743-754. DOI:10.1038/nrc2503.
[23]Heitzer E, Bambach I, Dandachi N, et al . PTCH promoter methylation at low level in sporadic basal cell carcinoma analysed by three different approaches[J]. Exp Dermatol, 2010, 19(10): 926-928. DOI:10.1111/j.1600-0625.2010.01120.x.
[24]Wu W, Zhang J, Yang H, et al . Examination of AKAP12 promoter methylation in skin cancer using methylation-sensitive high-resolution melting analysis[J]. Clin Exp Dermatol, 2011, 36(4): 381-385. DOI:10.1111/j.1365-2230.2010.03968.x.
[25]Wu X, Wu T, Li K, et al. The Mechanism and Influence of AKAP12 in Different Cancers[J]. Biomed Environ Sci, 2018, 31(12): 927-932. DOI:10.3967/bes2018.127.
[26]Bucko PJ, Scott JD. Drugs That Regulate Local Cell Signaling: AKAP Targeting as a Therapeutic Option[J]. Annu Rev Pharmacol Toxicol, 2021, 61: 361-379. DOI:10.1146/annurev-pharmtox-022420-112134.
[27]Lodygin D, Yazdi AS, Sander CA . Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma[J]. Oncogene, 2003, 22(35): 5519-5524. DOI:10.1038/sj.onc.1206854.
[28]Darr OA, Colacino JA, Tang AL, et al . Epigenetic alterations in metastatic cutaneous carcinoma[J]. Head Neck, 2015, 37(7): 994-1001. DOI:10.1002/hed.23701.
[29]Li L, Li F, Xia Y, et al . UVB induces cutaneous squamous cell carcinoma progression by de novo ID4 methylation via methylation regulating enzymes[J]. EBioMedicine, 2020, 57: 102835. DOI:10.1016/j.ebiom. 2020.102835.
[30]Ko EK, Capell BC. Methyltransferases in the Pathogenesis of Keratinocyte Cancers[J]. Cancers, 2021, 13(14): 3402. DOI:10.3390/cancers13143402.
[31]Zhao H, Ming T, Tang S, et al . Wnt signaling in colorectal cancer: pathogenic role and therapeutic target[J]. Mol Cancer, 2022, 21(1): 144. DOI:10.1186/s12943-022-01616-7.
[32]Lang CMR, Chan CK, Veltri A, et al . Wnt Signaling Pathways in Keratinocyte Carcinomas[J]. Cancers, 2019, 11(9): 1216. DOI:10.3390/cancers11091216.
[33]Murao K, Kubo Y, Ohtani N , et al. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways: Epigenetic abnormalities in cutaneous SCCs[J]. Br J Dermatol, 2006, 155(5): 999-1005. DOI:10.1111/j.1365-2133. 2006. 07487.x.
[34]Sharma P, Chinaranagari S, Patel D, et al . Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer[J]. Cancer Med, 2012, 1(2): 176-186. DOI:10.1002/cam4.16.
[35]Pan Y, Song Y, Cheng L, et al . Analysis of methylation-driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma[J]. J Cell Biochem, 2019, 120(12): 19482-19495. DOI:10.1002/jcb.29252.
[36]Venza M, Visalli M, Catalano T, et al . DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients[J]. Hum Pathol, 2017, 60: 137-146. DOI:10.1016/j.humpath.2016.10.018.
